Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 2,809-2,820 of 10,592
Drug study icon
CompletedNCT02969369

Safety study of SEP-363856 in Schizophrenia

This study is completed in the United States. It is testing SEP-363856 for Schizophrenia.

Remote / online
SchizophreniaDrugFrom 55 Years to 105 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT02417064

Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression

This study is completed in the United States, in France, in Canada, .... It is testing efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.

In United States
DepressionDrugFrom 18 Years to 64 Years
Countries
United States, France, Canada, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT02418585

Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression

This study is completed in the United States, in Czechia, in Germany, .... It is testing efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.

In United States
DepressionDrugFrom 18 Years to 64 Years
Countries
United States, Czechia, Germany, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT02422186

Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression

This study is completed in the United States, in France, in the United Kingdom, .... It is testing efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.

In United States
DepressionDrugOver 65 Years
Countries
United States, France, United Kingdom, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
CompletedNCT03745820

Safety study of Safety and Efficacy of BIIB104 in schizophrenia

This study is completed in the United States, in the United Kingdom, in Germany, .... It is testing Safety and Efficacy of BIIB104 for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States, United Kingdom, Germany, ...
Sponsor
Biogen
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.